Staff editor

Fermented Beetroot alters gut microbiota and prevents prediabetes in high-fat-fed mice 

Microbiomepost conducted an exclusive interview with Eric Daliri, from Vilnius University, about the possibility of prevent diabetes modulating gut microbiome.

Exploring the critical role of soil microbiome in sustaining civilization

Microbiomepost conducted an exclusive interview with Nina Vinot, Bioprox Healthcare, about the new frontiers of the microbiome revolution: the role of soil microbiome in the agriculture space.

Alessio Fasano – 10th International Human Microbiome Consortium (IHMC) Congress 2024 key highlights

Alessio Fasano, Chair of the Congress, shares an overview of the event and the future challenges.

From Biofarma Group a clinically validated product supporting a healthy vaginal microbiota

The Research and Development laboratories of Biofarma Group have developed a formulation that can represent a valid aid in case of vaginal dysbiosis and associated disorders.

Biocodex Microbiota Foundation launches 2024 USA research grant program

Key areas of interest include circadian rhythms, neurological conditions, metabolic disorders, and oncology.

George Paraskevakos at IPC 2024: trends and future challenges in the Biotic market

During IPC 2024, George Paraskevakos shared recent updates on market developments and an overview of the Biotic-related survey.

Nestlé Health Science acquires VOWST Assets

VOWST is the first and only orally administered microbiota-based therapeutic approved by the U.S. FDA for the prevention of recurrent Clostridioides difficile infection in adults.

Seed Health introduces revolutionary vaginal microbiome product: VS-01

The product, based on the pioneering research of Dr. Jacques Ravel, is the first of its kind to be clinically validated for establishing an optimal vaginal microbiome, dominated by Lactobacillus…

SynBalance Srl secures dual honors at 2024 NutraIngredients Awards

The company was honored with the Ingredient of the Year award in the Microbiome Modulation and the Beauty from Within category.

Biompharma’s Bi104 Receives FDA Orphan Drug Designation for Angelman Syndrome Treatment

Bi104 is a microbiome-modifying biologic designed to diversify and modulate the gut microflora and metabolite profile.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top